Entrada reports positive Phase 1/2 Cohort 1 data for Duchenne drug ENTR-601-44
PUBT · 6h ago
Share
Listen to the news
- Entrada Therapeutics reported positive topline results from Cohort 1 of Phase 1/2 ELEVATE-44-201 testing ENTR-601-44 in ambulatory Duchenne muscular dystrophy patients with mutations amenable to exon 44 skipping.
- Readout showed favorable safety and tolerability with no serious adverse events or discontinuations, supporting continued dose escalation in study.
- Treated participants showed early functional improvement versus placebo, despite lower-than-expected drug exposure in pediatric patients versus healthy adults.
- Dosing has started in Cohort 2 at higher dose, with additional results from Cohort 1 open-label extension and Cohort 2 expected by year-end 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved